Prospective Multicenter Study of Circulating Tumor Cell AR-V7 and Taxane Versus Hormonal Treatment Outcomes in Metastatic Castration-Resistant Prostate Cancer.
Andrew J ArmstrongJun LuoDavid M NanusParaskevi GiannakakouRussell Z SzmulewitzDaniel Costin DanilaPatrick HealyMonika AnandWilliam R BerryTian ZhangMichael R HarrisonChangxue LuYan ChenGiuseppe GallettiJoseph D SchonhoftHoward I ScherRichard WenstrupScott T TagawaEmmanuel S AntonarakisDaniel J GeorgeSusan HalabiPublished in: JCO precision oncology (2020)
Detection of AR-V7 in CTCs by two different blood-based assays is independently associated with shorter PFS and OS with abiraterone or enzalutamide, but such men with AR-V7-positive disease still experience clinical benefits from taxane chemotherapy.